Drug Trial Radar · NCT03384745
A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
Last checked: Nov 19, 2026Latest source record: Aug 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
313
Actual
Start
Jul 31, 2018
Primary completion
Jun 20, 2019
Study completion Mar 26, 2020
Sponsor
- Lead sponsor
- Bond Avillion 2 Development LPIndustry
- Sponsor type
- Industry
- Collaborators
- Avillion LLP
- First posted
- Dec 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center phase 2b study in subjects with moderate to severe chronic plaque-type psoriasis. Approximately 300 subjects will be enrolled at approximately 60 investigator sites in North America and Europe.
Conditions
- Psoriasis
Interventions
M1095 (Sonelokimab)Drug
M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
PlaceboDrug
Placebo contains no active drug.
SecukinumabDrug
Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1Time frame: Week 12, as compared to Week 0 (baseline)
Locations
60 sites in 7 countries. Site status is shown where the registry gives one.
Investigative Site
Birmingham, Alabama
Investigative Site
San Diego, California
Investigative Site
DeLand, Florida
Investigative Site
Sandy Springs, Georgia
Investigative Site
St Louis, Missouri
Investigative Site
Albuquerque, New Mexico
Investigative Site
New York, New York
Investigative Site
Bexley, Ohio
Investigative Site
Dallas, Texas
Investigative Site
Houston, Texas
Investigative Site
San Antonio, Texas
Investigative Site
Dupnitsa, Bulgaria
Investigative Site
Sofia, Bulgaria
Investigative Site
Varna, Bulgaria
Investigative Site
Edmonton, Alberta, Canada
Investigative Site
Surrey, British Columbia, Canada
Investigative Site
Surrey, British Columbia, Canada
Investigative Site
Markham, Ontario, Canada
Investigative Site
North Bay, Ontario, Canada
Investigative Site
Oakville, Ontario, Canada
Investigative Site
Ottawa, Ontario, Canada
Investigative Site
Richmond Hill, Ontario, Canada
Investigative Site
Waterloo, Ontario, Canada
Investigative Site
Windsor, Ontario, Canada
Investigative Site
Québec, Quebec, Canada
Investigative Site
Brno, Czechia
Investigative Site
Náchod, Czechia
Investigative Site
Nový Jičín, Czechia
Investigative Site
Ostrava, Czechia
Investigative Site
Ostrava, Czechia
Investigative Site
Pardubice, Czechia
Investigative Site
Prague, Czechia
Investigative Site
Uherské Hradiště, Czechia
Investigative Site
Augsburg, Germany
Investigative Site
Berlin, Germany
Investigative Site
Bochum, Germany
Investigative Site
Darmstadt, Germany
Investigative Site
Frankfurt am Main, Germany
Investigative Site
Friedrichshafen, Germany
Investigative Site
Hamburg, Germany
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.